US4540704A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treating complications of diabetes mellitus with hydantoin derivatives
Assignee: Eisai Co Ltd
•
Filing: 1983-06-07
•
Granted: 1985-09-10
•
Expires: 2003-06-07
Abstract
Abstract Novel hydantoin derivatives and salts thereof, the process for the preparation thereof, and medicines containing the same, wherein the hydantoin derivatives are represented by the general formula: ##STR1## wherein X 1 and X 2 , which may be the same or different, independently represent a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; Y represents an oxygen atom or sulfur atom, R 1 and R 2 , which may be the same or different, independently represent a hydrogen atom, a lower alkyl group or phenyl group, or both may form a ring with carbon atoms, excluding the case wherein both R 1 and R 2 are hydrogen atom, and n represents 0 or 1. The novel hydantoin derivatives and salts thereof have excellent effects for the treatment of the complications of diabetes mellitus.
Inventors
- 👤 Kouichiro Ueda
- 👤 Satoru Tanaka
- 👤 Toshinobu Kunii
- 👤 Kengo Kagei
- 👤 Tadashi Sato
- 👤 Ono Hideki
- 👤 Issei Ohtsuka
- 👤 Mayumi Kawase
- 👤 Toshiharu Ohgoh
- 👤 Tsuneo Wakabayashi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 07:25
CPC Classifications
C; C07; C07D; C07D493/00; C07D493/02; C07D493/10; A; A61; A61P; A61P25/00; A61P25/02; A61P27/00; A61P27/02; A61P27/12; A61P3/00; A61P3/08; A61P3/10; A61P9/00; A61P9/10; C07D495/00; C07D495/02; C07D495/10
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
71 words
A hydantoin derivative represented by the formula: ##STR16## wherein X 1 and X 2 , which may be the same or different, independently represent a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group, Y represents an oxygen atom or sulfur atom, R 1 represents hydrogen and R 2 represents a lower alkyl group, and n represents 0 or 1, or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
71 words
A hydantoin derivative represented by the formula: ##STR16## wherein X 1 and X 2 , which may be the same or different, independently represent a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group, Y represents an oxygen atom or sulfur atom, R 1 represents hydrogen and R 2 represents a lower alkyl group, and n represents 0 or 1, or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
69 words
The hydantoin derivative or salt thereof according to claim 1 wherein said hydantoin derivative is represented by the formula: ##STR17## wherein X 1 and X 2 , which may be the same or different, independently represent a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, R 1 represents hydrogen and R 2 represents a lower alkyl group, and n represents 0 or 1.
Claim 4
Dependent Claim
63 words
The hydantoin derivative or salt thereof according to claim 1, whrein said hydantoin derivative is represented by the formula: ##STR18## wherein X 1 and X 2 , which may be the same or different, independently represent a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group, R 1 represents hydrogen and R 2 represents a lower alkyl group.
Claim 5
Dependent Claim
16 words
The hydantoin derivative or salt thereof according to claim 1, wherein said hydantoin derivative is 6-fluoro-2-methyl-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione.
Claim 6
Dependent Claim
16 words
The hydantoin derivative or salt thereof according to claim 1, wherein said hydantoin derivative is 6-chloro-2-methyl-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione.
Claim 7
Dependent Claim
16 words
The hydantoin derivative or salt thereof according to claim 1, wherein said hydantoin derivative is 5-chloro-2-methyl-spiro-[benzofuran-3,4'-imidazolidine]-2',5'-dione.
Claim 8
Dependent Claim
16 words
The hydantoin derivative or salt thereof according to claim 1, wherein said hydantoin derivative is 6,7-dichloro-2-methyl-spiro-[chroman-4,4'-imidazolidine]-2,',5'-dione.
Claim 9
Dependent Claim
16 words
The hydantoin derivative or salt thereof according to claim 1, wherein said hydantoin derivative is 7-chloro-2-methyl-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione.
Claim 10
Dependent Claim
95 words
A pharmaceutical composition for the treatment of chronic complications of diabetes mellitus comprising an effective amount for such treatment of a hydantoin derivative represented by the formula: ##STR19## wherein X 1 and X 2 , which may be the same or different, independently represent a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group, Y represents an oxygen atom or sulfur atom, R 1 represents hydrogen and R 2 represents a lower alkyl group, and n represents 0 or 1, or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier.
Claim 11
Dependent Claim
95 words
A pharmaceutical composition for the treatment of chronic complications of diabetes mellitus comprising an effective amount for such treatment of a hydantoin derivative represented by the formula: ##STR19## wherein X 1 and X 2 , which may be the same or different, independently represent a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group, Y represents an oxygen atom or sulfur atom, R 1 represents hydrogen and R 2 represents a lower alkyl group, and n represents 0 or 1, or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier.
Claim 12
Dependent Claim
37 words
A method for treating chronic complications of diabetes mellitus which comprises administering to a patient suffering from such complications of diabetes mellitus an effective amount for treating such complication, of a hydantoin derivative according to claim 1.
Claim 13
Dependent Claim
30 words
The method according to claim 10, wherein said chronic complications are one or more of diabetic cateracts, diabetic neuropathy, fine blood vessel lesions, diabetic retinopathy and arteriosclerotic blood vessel lesions.
References Cited (Backward Citations)
US4117230A
Cited
US4181729A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-09-09 | 1989-03-11 | 1989-09-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-09-09 | 1993-03-11 | 1993-09-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-09-09 | 1997-03-11 | 1997-09-10 | $7700.00 | Window Closed / Lapsed |